氯氨苄头孢菌素(cafaclor)是一个新的抗生素,在治疗呼吸道感染时在细菌学和临床方面都很有疗效,例如对肺炎,支气管咽和咽炎。本研究选用最常用于治疗呼吸道感染的羟氨苄青霉素(amoxycill-in),与氯氨苄头孢菌素进行了单盲法的治疗研究,两者的剂量都是250mg 每日3次。共101例呼呼道感染病人,年龄9～77岁,51例用氯氨苄头孢菌素治疗,50例用羟氨苄青霉素治疗。共用药一周。 Ampicillin (cafaclor) is a new antibiotic that is both bacteriologically and clinically effective in the treatment of respiratory infections, such as pneumonia, bronchial pharynx and pharyngitis. This study selected amoxycill-in, the most commonly used therapy for respiratory infections, and was treated with a single-blinded study of cefotaxime, both in doses of 250 mg three times daily. A total of 101 cases of respiratory tract infection patients, aged 9 to 77 years, 51 cases treated with ampicillin, and 50 cases treated with amoxicillin. A total of one week medication.